Company Description
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool.
Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software.
Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 11, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,546 |
| CEO | Jon Resnick |
Contact Details
Address: 4 Radnor Corporate Center, Suite 350 Radnor, Pennsylvania 19087 United States | |
| Phone | 415 237 8272 |
| Website | certara.com |
Stock Details
| Ticker Symbol | CERT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001827090 |
| CUSIP Number | 15687V109 |
| ISIN Number | US15687V1098 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Jon Resnick | Chief Executive Officer and Director |
| Leif E. Pedersen | President and Chief Commercial Officer |
| John E. Gallagher III | SVice President, Principal Accounting Officer and Chief Financial Officer |
| Dr. Robert P. Aspbury Ph.D. | President of Certara Predictive Technologies |
| Dr. Christopher Bouton Ph.D. | Chief Technology Officer |
| Daniel D. Corcoran | Senior Vice President and General Counsel |
| Ron DiSantis | Senior Vice President of Corporate Development |
| Sheila Rocchio MBA | Chief Marketing Officer |
| Rona Anhalt | Chief Human Resources Officer |
| Dr. Frederic Yves Bois Ph.D., Pharm.D. | Senior Scientific Advisor, Head of Mechanistic Modeling and Member of Simcyp Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Dec 11, 2025 | 8-K | Current Report |
| Nov 25, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | SCHEDULE 13G | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Oct 16, 2025 | 8-K | Current Report |
| Oct 9, 2025 | SCHEDULE 13G | Filing |
| Oct 7, 2025 | SCHEDULE 13G/A | Filing |